International safety pharmacology guidelines (ICH S7A and S7B): Where do we go from here?

Drug Development Research

Volumn 64, Issue 2, 2005, Pages 83-89

  Porsolt, Roger D ^a   Picard, Sandra ^a   Lacroix, Pierre ^a  

^a Porsolt and Partners Pharmacology   (France)

Author keywords

Cardiovascular system; Central nervous system; Respiratory system; Risk assessment; Safety pharmacology

Indexed keywords

ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BARBITURIC ACID; BENZODIAZEPINE; CALCIUM CHANNEL STIMULATING AGENT; CLOZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OPIATE;

ACUTE TOXICITY; ANIMAL MODEL; ANIMAL WELFARE; ARRHYTHMOGENESIS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CONVULSION; DOG; DRUG SAFETY; GUINEA PIG; HEART ARRHYTHMIA; LD 50; LUNG MECHANICS; NONHUMAN; ORTHOSTATIC HYPERTENSION; PAIN; PULMONARY HYPERTENSION; RAT; RESPIRATION CONTROL; RESPIRATORY SYSTEM; REVIEW; SLEEP; TORSADE DES POINTES; TOXICITY TESTING;

EID: 19944391591     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10411     Document Type: Review

References (12)

1. Anon. 1995. Japanese guidelines for Nonclinical Studies of Drugs Manual, Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare, Yakugi Nippo, Tokyo.
2. Anon. 2000. ICH S7A: Safety Pharmacology studies for human pharmaceuticals. European Agency for the Evaluation of Medicinal Products. Evaluation of Medicines for Human Use. CPMP/ICH/539/00, London, November 16, 2000.
3. Anon. 2004. ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Step 2 Revision. US Food and Drug Administration, Department of Health and Human Services, Rockville, MD 20857-0001, June 10, 2004.
4. Antzelevitch C, Sicouri S. 1994. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 23:259-277.
5. Bigelow GE. 1991. Draft Guidelines for Abuse Liability Assessment. Drug Abuse Advisory Committee, FDA, US Public Health Service, Washington D.C.
6. Dumotier BM, Adamantidis MM, Puisieux FL, Bastide MB, Dupuis BA. 1999. Repercussions of pharmacologic reduction in ionic currents on action potential configuration in rabbit Purkinje fibers: are they indicative of proarrhythmic potential? Drug Dev Res 47:63-76.
7. Franklin KB. 1998. Analgesia and abuse potential: an accidental association or a common substrate? Pharmacol Biochem Behav 59:993-1002.
8. Hashimoto Y, Ohashi R, Minami K, Narita H. 1999. Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Jpn J Pharmacol 81:63-72.
9. Murphy DJ. 2002. Assessment of respiratory function in safety pharmacology. Fund Clin Pharmacol 16:183-196.
10. Picard S, Rouet R, Monti F, Puddu PE, Ducouret P, Flais F, Libersa C, Gérard JL. 1998. Proarrhythmic effects of DL- and D-sotalol on the "border zone" between normal and ischemic regions on isolated ventricular myocardium and antiarrhythmic effects on reperfusion. J Cardiovasc Pharmacol 31: 126-139.
11. Porsolt RD, Lemaire M, Dürmüller N, Roux S. 2002. New perspectives in CNS safety pharmacology. Fund Clin Pharmacol 16:197-207.
12. Van den Hoogen RH, Colpaert FC. 1986. Respiratory effects of morphine in awake unrestrained rats. J Pharmacol Exp Ther 237:252-259.